Dr. Graham G. Walmsley is an Independent Director at Olema Pharmaceuticals, Inc., a Managing Member at Logos Capital Fund LLP, a General Partner at Logos Global Management LP and an Independent Non-Executive Director at Akero Therapeutics, Inc.
He is on the Board of Directors at Olema Pharmaceuticals, Inc., ALX Oncology, Inc. and Akero Therapeutics, Inc. Prior to Logos, Dr. Walmsley was a Principal and Manager of the crossover fund at Versant Ventures where he invested in biotechnology companies across multiple funds totaling over $1.5 billion in AUM. While at Versant, Dr. Walmsley served as a board director, built and launched multiple companies (including BlueRock Therapeutics acquired by Bayer), and was head of business development for Jecure Therapeutics through its acquisition by Roche.
He holds an MD and PhD from Stanford University School of Medicine.